A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates.
about
Rabbit as a novel animal model for hepatitis E virus infection and vaccine evaluationHepatitis E virus as an emerging zoonotic pathogenCurrent Knowledge on Hepatitis ELessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteinsDimerization of Hepatitis E Virus Capsid Protein E2s Domain Is Essential for Virus–Host InteractionMolecular Biology and Infection of Hepatitis E VirusEpidemiology of Hepatitis E in Pregnant Women and Children in Iran: A General OverviewToolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccineChemically activatable viral capsid functionalized for cancer targetingSubviral particle as vaccine and vaccine platform.HEV-Capsid Protein Interacts With Cytochrome P4502C8 and Retinol-Binding Protein 4.Molecular virology of hepatitis E virus.The development of a recombinant hepatitis E vaccine HEV 239.Three amino acid mutations (F51L, T59A, and S390L) in the capsid protein of the hepatitis E virus collectively contribute to virus attenuation.Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis.Detection of serum antibodies to hepatitis E virus in domestic pigs in Italy using a recombinant swine HEV capsid proteinA valuable antigen detection method for diagnosis of acute hepatitis E.Enhanced mucosal immune responses induced by a combined candidate mucosal vaccine based on Hepatitis A virus and Hepatitis E virus structural proteins linked to tuftsinIdentification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody.Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody.Enhanced humoral response in pregnant mice immunized with liposome encapsulated recombinant neutralizing epitope protein of Hepatitis- E virus.Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment.Seroprevalence of hepatitis E virus infection, rural southern People's Republic of China.Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus.Assessment of the cross-protective capability of recombinant capsid proteins derived from pig, rat, and avian hepatitis E viruses (HEV) against challenge with a genotype 3 HEV in pigs.Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice.A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus.Hepatitis E virus capsid protein assembles in 4M urea in the presence of salts.A high-throughput neutralizing assay for antibodies and sera against hepatitis E virusDevelopment and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus.Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy.A preliminary cost-effectiveness analysis of hepatitis E vaccination among pregnant women in epidemic regionsHepatitis E vaccine.Hepatitis E virus: Current epidemiology and vaccine.Hepatitis E virus infections in humans and animalsA dual vaccine candidate against norovirus and hepatitis E virus.Management of hepatitis E virus (HEV) zoonotic transmission: protection of rabbits against HEV challenge following immunization with HEV 239 vaccine.Hepatitis E virus infection.Host immune status and response to hepatitis E virus infection.Hepatitis e: molecular virology and pathogenesis.
P2860
Q21090828-AF5EEA3D-BBDA-477D-968B-D91DB64E1443Q26751267-92597A0F-42DC-4106-A6DA-6BF7AD27B8C5Q26782030-840CAB0E-0E23-429E-9180-DD613AC50945Q27013018-7AED4AD4-6ABF-44E0-8E3D-9A36AC45A389Q27656916-933E8C91-CEF8-40FF-95D4-E5AB177C1415Q28066101-F5F4B3D3-AB93-4B85-BE92-36D02886F4BCQ28072683-6E574DFA-12EA-4FA3-AB87-2804C638306AQ28730718-9D292B58-05F8-41E5-9175-164C67862321Q28830058-CE6E795B-7152-4494-BB4D-3325EDA7B04AQ33812653-7315BAFB-7DFE-47F7-9D7F-9E2E6DC31CA9Q34151626-8E4AD10F-95B3-42A2-AED2-B5C1C95DF068Q34166393-100871B4-FF0F-4B8A-9349-B49802AF7293Q34464464-9B0F5986-10F0-4A2F-AACE-2F2991AE4A2BQ34982710-7E1AD59D-3E70-4E2E-87CD-51354D9E038BQ35073715-664C533A-304E-4EF8-B6CC-07BBD4FB9FA8Q35189231-E31FFF15-CD02-4FDB-B835-AB5AAFD780EEQ35331616-353E9579-08A3-428C-B4B6-0490B3587F54Q35391544-57E29B76-9B7F-4407-A78B-02D75D0CAC38Q35532771-543E7934-7F16-45A4-BF91-F3E30BDC53FBQ35578943-FBB86D83-A1A3-4507-A220-240D5C1FC909Q35683323-350EDCD1-8036-485E-9C35-232A102804FEQ35887653-D5FC1E16-3BFD-4DA1-8A87-A7CB46355C12Q36023562-879D5DA3-8FC0-43F0-B5BF-9B890E245DF0Q36134262-08325A00-2C7D-4DE3-9343-CE68CBE32E85Q36245120-A56EF29F-BA98-4D81-AB5B-87F3C19CFDA9Q36256455-BA5CD3AA-4E71-443C-A767-2B2F5AE99E85Q36519453-C7B9CFE0-495B-492F-B0A5-75907AC755F3Q36678270-C34E8FAA-1478-4FF5-847F-B250A4C4329FQ36845713-79F196A6-12FD-4569-A30F-68A18E976A7BQ36914794-8FC42E7B-F472-4701-8D4B-699BEB62447CQ36973372-85B2F45D-2FF2-452C-9433-CB18380598ABQ37197088-91DDA134-394E-43D8-81FF-4CBF8AFE3D12Q37278231-14AEDEFC-E82E-4BD4-A265-464F09D18825Q37375936-A6F6CE72-BB88-4064-B984-2EB2D5264411Q37473517-E383AE44-B442-40FD-BA62-ED4C4480A1BBQ37502688-154045D8-6878-480F-B4D8-931AC491C981Q37534616-22332150-07B1-4292-A4E7-DFE3FB9B2423Q37544935-3E3BD781-5FE8-46E8-A0B0-7BDD6441B901Q37544940-9EFF2C9B-AD71-4658-9A6E-70FB09D46A2AQ37613164-21EEE27F-E312-42CE-81AC-AAB1B4AB21BC
P2860
A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A bacterially expressed partic ...... and protectivity on primates.
@en
A bacterially expressed partic ...... and protectivity on primates.
@nl
type
label
A bacterially expressed partic ...... and protectivity on primates.
@en
A bacterially expressed partic ...... and protectivity on primates.
@nl
prefLabel
A bacterially expressed partic ...... and protectivity on primates.
@en
A bacterially expressed partic ...... and protectivity on primates.
@nl
P2093
P1433
P1476
A bacterially expressed partic ...... y and protectivity on primates
@en
P2093
Guo Y Huang
Ning S Xia
Sheng X Ge
Shu Q Pang
Yang L Xian
P304
P356
10.1016/J.VACCINE.2004.11.064
P407
P50
P577
2005-04-01T00:00:00Z